- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–12 of 25
Explanation of Distal Filter Embolic Protection Devices Included in the CER
Current Practice for Patients Undergoing PCI
Overall Conclusions
Rationale for Update
Evidence of Benefits: Clinical Outcomes
Keywords: clinical outcomes | ACEIs | ARBs | mortality | cardiovascular events | serum lipid levels | renal disease | quality of life
Standard Therapy for Stable Ischemic Heart Disease
Guidelines for the Use of ACEIs, ARBs, or Both to Treat Patients With Cardiac Disease (1)
Pharmacologic Effects of Antagonists on the Renin-Angiotensin-Aldosterone System
Results of Trials Evaluating the Addition of an ACEI or an ARB to Standard Therapy for Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function
Benefits With HIGH Levels of Evidence That Result From Adding an ARB to Standard Medical Therapy for Stable Ischemic Heart Disease With Preserved Left Ventricular Systolic Function*
Background: Management
Overview of Adverse Events and Side Effects
Presentation: Comparing Medications for Adults With Type 2 Diabetes
Your slide tray is being processed.